{"id":250114,"date":"2023-01-10T00:00:00","date_gmt":"2023-01-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0074-biopharma-acute-myeloid-leukemia-epidemiology-emerging\/"},"modified":"2026-03-31T10:35:14","modified_gmt":"2026-03-31T10:35:14","slug":"epidon0074-biopharma-acute-myeloid-leukemia-epidemiology-emerging-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0074-biopharma-acute-myeloid-leukemia-epidemiology-emerging-markets\/","title":{"rendered":"Acute Myeloid Leukemia &#8211; Epidemiology &#8211; Emerging Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of acute myeloid leukemia (<abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and Europe and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr>, how many in each country in the developed world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 17 <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> patient populations, including the following:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases.<\/li>\n<li>Diagnosed incident cases by FLT3 mutation status.<\/li>\n<li>Diagnosed incident cases by cytogenetic risk status.<\/li>\n<li>Diagnosed first-line <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> younger patients (aged < 60) drug-treatable population.<\/li>\n<li>Diagnosed first-line <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> younger patients (aged < 60) drug-treated population.<\/li>\n<li>Diagnosed second-line <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> younger patients (aged < 60) drug-treatable population.<\/li>\n<li>Diagnosed second-line <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> younger patients (aged < 60) drug-treated population.<\/li>\n<li>Diagnosed first-line <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> older patients (aged \u2265 60) drug-treatable population.<\/li>\n<li>Diagnosed first-line <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> older patients (aged \u2265 60) drug-treated population.<\/li>\n<li>Diagnosed second-line <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> older patients (aged \u2265 60) drug-treatable population.<\/li>\n<li>Diagnosed second-line <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> older patients (aged \u2265 60) drug-treated population.<\/li>\n<li>Diagnosed third-line <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> drug-treatable population.<\/li>\n<li>Diagnosed third-line <abbr data-abbreviation-entity=\"4730\" title=\"acute myeloid leukemia\">AML<\/abbr> drug-treated population.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250114","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-myeloid-leukemia","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250114\/revisions"}],"predecessor-version":[{"id":576131,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250114\/revisions\/576131"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}